CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

The Turkish Journal of Pharmaceutical Sciences, an esteemed publication by GALENOS PUBL HOUSE, has been a prominent platform for research and innovation in the fields of Pharmaceutical Sciences and Molecular Medicine since its inception as an Open Access journal in 2004. Based in Turkey, this journal serves as a vital resource for researchers, professionals, and students keen on exploring the latest advancements in drug development, pharmacology, and therapeutic innovations. With an ISSN of 1304-530X and an E-ISSN of 2148-6247, the journal is indexed in leading databases and has demonstrated strong rankings in the Scopus index, notably securing the second quartile in Pharmaceutical Sciences. Furthermore, it fosters academic collaboration and knowledge dissemination by making its content freely accessible. The journal aims to inspire groundbreaking research, providing an important academic forum for the dissemination of valuable insights that impact the pharmaceutical sector and contribute to global health.

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.